| TKPHF Stock | | | USD 25.26 0.29 1.14% |
CEO
Mr. Christophe Weber was serving as President, Chief Executive Officer and Representative Director in Takeda Pharmaceutical Company Limited since April 1, 2015. He used to work for GlaxoSmithKline K.K. since 2015.
| Age | 57 |
| Tenure | 9 years |
| Phone | 81 3 3278 2111 |
| Web | https://www.takeda.com |
Takeda Pharmaceutical Management Efficiency
The company has return on total asset
(ROA) of
0.0247 % which means that it generated a profit of $0.0247 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.0477 %, meaning that it generated $0.0477 on every $100 dollars invested by stockholders. Takeda Pharmaceutical's management efficiency ratios could be used to measure how well Takeda Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.
Takeda Pharmaceutical Co has accumulated 4.14
T in total debt with debt to equity ratio
(D/E) of 0.81, which is about average as compared to similar companies. Takeda Pharmaceutical has a current ratio of 1.16, suggesting that it
may have difficulties to pay its financial obligations in time and when they become due. Debt can assist Takeda Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Takeda Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Takeda Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Takeda to invest in growth at high rates of return. When we think about Takeda Pharmaceutical's use of debt, we should always consider it together with cash and equity.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan. Takeda Pharmaceutica operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 47347 people. Takeda Pharmaceutical Co [TKPHF] is a
Pink Sheet which is traded between brokers as part of OTC trading.
Management Performance
Takeda Pharmaceutical Leadership Team
Elected by the shareholders, the Takeda Pharmaceutical's board of directors comprises two types of representatives: Takeda Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Takeda. The board's role is to monitor Takeda Pharmaceutical's management team and ensure that shareholders' interests are well served. Takeda Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Takeda Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christophe Weber, CEO and President and Representative Director | |
| Christopher OReilly, Global Fin | |
| Andrew Plump, Chief Medical and Scientific Officer and Corporate Officer | |
| Seigo Izumo, Chair Board | |
| Gabriele Ricci, Chief Officer | |
| Salvatore Alesci, Member Policy | |
| Iwaaki Taniguchi, Sr Department | |
| Constantine Saroukos, CFO Director | |
| Haruhiko Hirate, Member Board | |
| Norimasa Takeda, Chief Controller | |
Takeda Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Takeda Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Takeda Pink Sheet
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company
management, corporate governance, and ethical practices play a significant role. A
comparison with peer companies also provides context and helps to understand if Takeda Pink Sheet is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock.
Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock: Check out
World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in rate.
You can also try the
Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.